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ABSTRACT
Background: Isolated, primary synovial fibroblasts
generate active glucocorticoids through expression of
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1).
This enzyme produces cortisol from inactive cortisone
(and prednisolone from prednisone).
Objective: To determine how intact synovial tissue
metabolises glucocorticoids and to identify the local and
systemic consequences of this activity by examination of
glucocorticoid metabolism in patients with rheumatoid
arthritis (RA).
Methods: Synovial tissue was taken from patients with
RA during joint replacement surgery. Glucocorticoid
metabolism in explants was assessed by thin-layer
chromatography and specific enzyme inhibitors. RT-PCR
and immunohistochemistry were used to determine
expression and distribution of 11b-HSD enzymes.
Systemic glucocorticoid metabolism was examined in
patients with RA using gas chromatography/mass
spectrometry.
Results: Synovial tissue synthesised cortisol from
cortisone, confirming functional 11b-HSD1 expression. In
patients with RA, enzyme activity correlated with donor
erythrocyte sedimentation rate (ESR). Synovial tissues
could also convert cortisol back to cortisone. Inhibitor
studies and immunohistochemistry suggested this was
owing to 11b-HSD2 expression in synovial macrophages,
whereas 11b-HSD1 expression occurred primarily in
fibroblasts. Synovial fluids exhibited lower cortisone levels
than matched serum samples, indicating net local steroid
activation. Urinary analyses indicated high 11b-HSD1
activity in untreated patients with RA compared with
controls and a significant correlation between total body
11b-HSD1 activity and ESR.
Conclusions: Synovial tissue metabolises glucocorti-
coids, the predominant effect being glucocorticoid
activation, and this increases with inflammation.
Endogenous glucocorticoid production in the joint is likely
to have an impact on local inflammation and bone
integrity.
Since the discovery of cortisone and its first use in
patients with rheumatoid arthritis (RA)1 glucocor-
ticoids have been extensively used to suppress
synovial inflammation. However, in patients with
established synovitis, glucocorticoids such as corti-
sol (hydrocortisone), prednisone and prednisolone
do not cause permanent resolution of inflamma-
tion and long-term use has adverse effects on
bone, skin and fat tissue.2 3 Endogenous glucocor-
ticoids also have a role in suppressing disease
activity in RA. Early morning stiffness is attributed
to the nocturnal decrease in circulating cortisol
levels. Administration of metyrapone to reduce
endogenous corticosteroid production increases
disease activity in RA.4 It is unclear, however,
whether endogenous corticosteroid action contri-
butes to susceptibility to, or severity of, RA. Subtle
abnormalities of the hypothalamic-pituitary-
adrenal axis have been seen in glucocorticoid-naive
patients with RA5–7 but their origin remains
unclear.8
We have previously hypothesised that periarti-
cular osteopenia in RA is partly due to excessive
local glucocorticoid activation through the 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1)
enzyme.9 This enzyme converts inactive steroids
(cortisone and prednisone) to their active counter-
parts (cortisol and prednisolone).10 Although 11b-
HSD1 is bidirectional, its predominant action in
vivo is conversion of inactive to active glucocorti-
coids. Hepatic 11b-HSD1 is essential for activation
of oral cortisone/prednisone—patients who lack
this enzyme are unresponsive to cortisone and
prednisone but respond to hydrocortisone and
prednisolone.11 We have reported that synovial
fibroblasts express 11b-HSD1 in vitro and in vivo.12
In osteoblasts and synovial cells 11b-HSD1 activity
is upregulated by proinflammatory cytokines.9 12
This suggested that 11b-HSD1 might generate high
levels of glucocorticoids within the joint and that
this might contribute to periarticular osteopenia.
By contrast, a related enzyme 11b-HSD2 solely
inactivates steroids. This enzyme is expressed in
mineralocorticoid target tissues, various develop-
mental tissues and some tumours.13–15 Recent
studies have reported expression of 11b-HSD2 in
peripheral blood mononuclear cells (PBMCs) and
synovium of patients with RA.16–18 We therefore
examined glucocorticoid metabolism and function
in synovial tissue from patients with RA using
specific enzyme assays and inhibitors. In addition,
we examined glucocorticoid concentrations in
synovial fluid and compared the systemic metabo-
lism of glucocorticoids in patients with RA and
non-inflammatory joint conditions.
PATIENTS AND METHODS
Patients
Biopsy specimens of matched synovium and skin
were obtained during hip, knee or elbow arthro-
plasty from consenting patients who fulfilled the
American College of Rheumatology criteria for RA
and OA. Table 1 gives clinical details of the
patients.
Synovial tissue was taken on ice and prepared
within 2 h by removing adherent non-synovial
tissue. Tissue was divided into 100 mg sections for
enzyme assay or ELISA. Skin tissue was prepared
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by removing subcutaneous fat and dividing into 100 mg pieces.
Matched synovial fluid and serum samples were obtained
from patients with active RA undergoing joint aspiration as part
of routine care. Blood was drawn immediately before joint
aspiration. Clinical details are given online in supplementary
table 1.
Urine samples for corticosteroid metabolite analysis were
obtained from patients with newly presenting RA or non-
inflammatory joint disease (localised OA (n = 5); trigger finger
(n = 3); hypermobility (n = 1)). Clinical details are given in
supplementary table 2.
All studies had ethical approval from the local ethics
committee and informed consent was obtained when samples
were taken.
11b-Hydroxysteroid dehydrogenase enzyme assays
Synovial or skin tissue (100 mg per assay) was incubated in
RPMI-1640 medium containing 1% non-essential amino acids,
1% penicillin/streptomycin, 1% sodium pyruvate, 2 mM gluta-
mine and 20% heat-inactivated fetal calf serum (FCS; Labtech
International, Sussex, UK). Cortisol (100 nM; to measure
glucocorticoid inactivation) or cortisone (to measure activation)
along with tracer amounts of [3H]cortisol (specific activity 78.4
Ci/mmol; NEN Life Science Products, Hounslow, UK) or
[3H]cortisone (generated as previously described19) were added
and tissue incubated at 37uC for 18 h. Similar assays were
performed using [3H]prednisolone or [3H]prednisone.20 Steroids
were extracted from medium/tissue using dichloromethane (5–
7 ml) and separated by thin-layer chromatography using
ethanol:chloroform as the mobile phase. Thin-layer chromato-
graphy plates were analysed using a Bioscan imager (Bioscan,
Washington DC, USA) and fractional steroid conversion
calculated. Results were expressed as pmol product/mg tissue/
h. Experiments were carried out in duplicate or triplicate.
RNA extraction and reverse transcription
RNA was extracted from synovium using a single-step method
(TRI Reagent, Sigma, Poole, UK). Aliquots (1 mg) of RNA were
reverse transcribed using random hexamers in a 20 ml volume
according to the manufacturer’s protocol (Promega, Madison,
USA).
Real-time PCR
Expression of mRNA for 11b-HSD1/2 was assessed by real-time
PCR in an ABI 7500 system (Applied Biosytems, Warrington,
UK). Reactions were performed in 25 ml aliquots on a 96-well
plate (Sigma). Primers for 18S were used as an internal
reference. Reactions contained TaqMan PCR master mix
(Applied Biosytems), 900 nmol primers, 100–200 nmol
TaqMan probe and 25–50 ng cDNA. Reactions were as follows:
50uC for 2 min, 95uC for 10 min, 44 cycles of 95uC for 15 s and
60uC for 1 min. Data were obtained as Ct values (cycle number
at which logarithmic PCR plots cross a calculated threshold line)
according to the manufacture’s guidelines, and used to
determine DCt values (Ct of target gene – Ct of housekeeping
gene) as raw data for gene expression. Probe and primer
sequences were 11b-HSD1:
forward AGGAAAGCTCATGGGAGGACTAG,
reverse ATGGTGAATATCATCATGAAAAAGATTC,
probe CATGCTCATTCTCAACCACATCACCAACA;
11b-HSD2: forward CAGGTGTCCTAGTGCACATTGAC,
reverse GTAGCCCACTCTCTCGTCCAA,
probe AAGGCACGCCCTCCCAGCG.
Immunohistochemistry
Cryostat sections of synovial tissue were analysed with
previously validated sheep polyclonal antibodies to 11b-HSD1
and 11b-HSD2 1/50 (The Binding Site, Birmingham, UK)14 21
with anti-sheep/goat biotin AB360 as secondary antibody 1/50.
Immunohistochemistry was also carried out using polyclonal
antisera to the endothelial marker von Willebrand’s factor 1/
1000 (Dako, Ely, UK); the fibroblast marker ASO2 (CD90) 1/
100 (Invitrogen, Paisley, UK); and the monocyte/macrophage
marker CD68 1/100 (BD Biosciences, New Jersey, USA).
Immunohistochemical analyses were carried out as described
previously.12
Measurement of corticosteroid levels in serum and synovial
fluids
Serum and synovial fluid cortisol and cortisone levels were
measured using a specific cortisol ELISA (R&D Systems,
Abingdon, UK) and a previously reported radioimmunoassay
for cortisone.22 Since serum and synovial fluid samples contain
cortisol-binding proteins these techniques only give information
about total cortisol concentration (rather than unbound ‘‘free’’
levels).23 Because there is much less protein binding of cortisone,
levels of cortisone ascertained by these methods are more likely
to reflect ‘‘free’’ levels.22
Measurement of urinary corticosteroid metabolites
The gas chromatography–mass spectrometry method was based
on Palermo et al24 using a 5970 mass spectrometer (Hewlett-
Packard, Houston, Texas, USA). Intra-assay and interassay
coefficients of variation were ,10% for cortisol and cortisone.
Table 1 Clinical characteristics of subjects for synovial tissue corticosteroid metabolism studies
Patients
Age (years)
Mean (SD) F/M (n)
Site of
operation
(n)
Treatment
(n)
ESR
(mm/1st h)
Mean (SD)
CRP
(mg/l)
Mean (SD)
With RA (n = 12) 62 (10) 11/1 Hip (6)
Knee (4)
Elbow (2)
Methotrexate (3)
Prednisolone (3)
Anti-TNF (2)
Sulfasalazine (1)
Hydroxychloroquine (1)
Azathioprine (1)
39 (20) 27 (23)
With OA (n = 8) 67 (7) 6/2 Hip (7)
Knee (1)
14 (11)*
*p,0.05 compared with patients with rheumatoid arthritis.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; OA, osteoarthritis; RA, rheumatoid arthritis; TNF, tumour necrosis
factor.
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11b-HSD1 activity was calculated as the tetrahydrocortisol +
allo-tetrahydrocortisol/tetrahydrocortisone ((THF+alloTHF)/
THE) ratio. Renal 11b-HSD2 activity was calculated as the
urinary-free cortisol/cortisone ratio (UFF/UFE). The sum of
total corticosteroid metabolites (THF, alloTHF, THE, cortols,
cortolones, UFF, UFE) was used as an index of total cortisol
secretion.
Analysis of interleukin 6 (IL6) levels by ELISA
Soluble IL6 in tissue supernatants was measured using a
sandwich ELISA (BD Biosciences Pharmingen, Torreyana, San
Diego, USA). The limit of detection was 2.2 pg/ml and intra-
assay and interassay coefficients of variation were 5.2% and
9.3%. Data were expressed as pg IL6/mg tissue.
Statistics
Data were reported as the mean (SD) of replicate mean values
for separate synovial explants unless otherwise stated.
Regression analysis was performed using Microsoft Excel
2003. One-way analysis of variance was performed using SPSS
Data Editor.
RESULTS
Enzyme activity studies
11b-HSD enzyme activity was present in all synovial samples
from patients with RA (fig 1). Activity was also present in
synovium from patients with osteoarthritis (OA). Activity was
bidirectional in all cases, although the relative amounts of
Figure 1 Glucocorticoid metabolism in
synovial explants taken from patients
with rheumatoid arthritis (RA) and
osteoarthritis (OA). The ability of synovial
tissue to interconvert cortisone and
cortisol was examined using tissue
freshly isolated after joint replacement
surgery. Data are steroid generation for
each sample adjusted for protein content
and assay time and are expressed as
mean (SD) of samples from each patient.
Figure 2 Relationship between glucocorticoid activating capacity of synovial explants and the systemic inflammatory response and the effect of a
specific inhibitor of 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) on glucocorticoid activation and inactivation. (A) A significant correlation
was seen between glucocorticoid activation (oxoreductase activity) and the erythrocyte sedimentation rate (ESR) measured before surgery in patients
with rheumatoid arthritis (RA). (B) The effect of PF-877423, a specific bidirectional inhibitor of 11b-HSD1 enzyme activity, on glucocorticoid activation
(oxoreductase activity, cortisone to cortisol conversion) and inactivation (dehydrogenase activity, cortisol to cortisone conversion) in synovium from
patients with RA or osteoarthritis (OA). The inhibitor reduced the capacity of synovium to activate glucocorticoids but was unable to block the
inactivating capacity. In OA tissue inactivation increased with 11b-HSD1 inhibition. These results indicate that the inactivating capacity is not due to
11b-HSD1.
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activation (cortisone to cortisol conversion) to inactivation
(cortisol to cortisone) varied between subjects. There was no
significant difference between RA and OA synovium in overall
levels of each activity or in the ratio of activation to
inactivation. Compared with patient-matched skin samples
synovial samples had greater mean (SE) activating capacity
(14.1 (1.8) vs 8.9 (1.3) pmol/mg protein/h; p,0.001) and a
higher ratio of activation to inactivation (ratio 1.7 (0.4) vs 0.6
(0.1); p,0.01), but there was no difference in inactivating
capacity (16.1 (3.5) vs 20.1 (3.4); NS). For glucocorticoid
activation in synovium there was a significant positive
correlation with the preoperative erythrocyte sedimentation
rate (ESR; fig 2A), but this relationship was not seen with
CRP (r2 = 0.04, NS). Inactivation did not correlate with
either inflammatory marker. Synovial tissue also metabolised
prednisone and prednisolone in a manner indistinguishable
from cortisone/cortisol (for 100 nM substrate activation
assay: cortisone to cortisol 16.3 (4.7) pmol/mg protein/h,
prednisone to prednisolone 23.0 (5.1); for inactivation assay;
cortisol to cortisone 15.2 (6.1), prednisolone to prednisone
12.5 (4.7); n = 4, NS).
Characterisation of glucocorticoid inactivating capacity
The glucocorticoid activating (oxoreductase) capacity of syno-
vial tissue appeared to be due to expression of 11b-HSD1 as this
is the only enzyme known to convert cortisone to cortisol.
Additionally, we have previously localised 11b-HSD1 in
synovium by immunohistochemistry12 and RT-PCR on synovial
tissue demonstrated abundant 11b-HSD1 mRNA expression (Ct
value 32.0 (0.7) relative to 12.9 (1.9) for 18S).
The glucocorticoid inactivating (dehydrogenase) activity
could be due to either 11b-HSD1, 11b-HSD2 or a combination
of both. The lack of correlation between activation and
inactivation (p = 0.56) suggested the presence of more than
one enzyme and a specific inhibitor of 11b-HSD1 (PF-877423;
Pfizer, New York, USA) was used to clarify this further. PF-
877423 blocks both activating (oxoreductase) and inactivating
(dehydrogenase) directions of 11b-HSD1 but has no effect on
11b-HSD2 activity (Bujalska et al, submitted for publication).
Enzyme activity data indicated that the inhibitor reduced
glucocorticoid activation in synovial tissue from patients with
RA and OA but increased glucocorticoid inactivation in OA
tissue (fig 2B). There was also a trend towards higher
Figure 3 Immunohistological
localisation of 11b-hydroxysteroid
dehydrogenase (11b-HSD) enzymes in
synovium. The expression of 11b-HSD1
and 11b-HSD2 within rheumatoid
synovium were examined using specific
antibodies. 11b-HSD1 expression
colocalised predominantly with a
fibroblast marker. Expression of 11b-
HSD2 colocalised with expression of
CD68.
Figure 4 The functional effect of glucocorticoid activation on interleukin 6 (IL6) synthesis in patients with rheumatoid arthritis (RA) and osteoarthritis
(OA). (A) Synovial tissue was incubated for 24 h in the presence or absence of 100 nM cortisone. In both RA and OA synovium cortisone had a
significant suppressive effect on IL6 production. (B) A specific 11b-HSD1 inhibitor (PF-877423) was able to block the decrease in IL6 production caused
by cortisone treatment.
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inactivation in RA tissue treated with inhibitor (p = 0.07).
These observations suggested that glucocorticoid inactivation in
synovial tissue was due to expression of 11b-HSD2 rather than
11b-HSD1. 11b-HSD2 was detectable by RT-PCR on RNA
extracted from synovial tissue (Ct 33.6 (1.0) relative to 12.1
(1.8) for 18S). Immunohistochemistry for 11b-HSD2 demon-
strated expression of the enzyme in both RA and OA tissue,
where it colocalised predominantly with CD68-positive macro-
phages (fig 3). This contrasted with 11b-HSD1 expression
which was localised primarily to fibroblasts.
Functional consequences of enzyme activity
High levels of IL6 were produced by synovial tissue. As
expected, levels were higher in patients with RA than in those
with OA. Incubation of synovial tissue with cortisol signifi-
cantly reduced IL6 production, indicating tissue sensitivity to
glucocorticoids. Incubation with cortisone also caused a
significant reduction in IL6 expression, suggesting that synovial
11b-HSD1 was functionally active, converting cortisone to
cortisol in an autocrine fashion (fig 4A). This was confirmed by
studies using PF-877423, which blocked the suppressive effect of
cortisone on IL6 (fig 4B).
Measurement of tissue glucocorticoid levels in vivo
To evaluate net synovial tissue glucocorticoid metabolism
within the joint we measured corticosteroid levels in
paired serum and synovial fluid samples. To minimise the
confounding effect of cortisol-binding proteins we measured
serum-to-synovial fluid concentration gradients in cortisone
since cortisone has limited binding to these proteins. Cortisone
levels in synovial fluid obtained from patients with RA were
significantly different from plasma levels (serum 56.7
(11.8) nmol/l, synovial fluid 20.9 (8.7) nmol/l; mean fall from
serum to synovial fluid 63%, p,0.001). The low cortisone levels
in synovial fluid suggested local net conversion of cortisone to
cortisol.
Measures of systemic glucocorticoid metabolism in
inflammatory arthritis
Systemic measures of 11b-HSD1 activity were assessed in
subjects with untreated RA compared with patients with non-
inflammatory joint disease. There was a significantly higher
ratio of cortisol to cortisone metabolites in the urine of patients
with RA, suggesting higher 11b-HSD1 activity (figs 5A and B).
No change was seen in the ratio of urinary cortisol to cortisone
indicating that renal 11b-HSD2 was unchanged. There was a
positive correlation between 11b-HSD1 activity and ESR (but
not CRP) in patients with RA (figs 5C and D). The urinary
cortisol/cortisone ratio also correlated with ESR in patients
with RA (r = 0.42, p,0.05) probably reflecting the contribution
11b-HSD1 makes to this ratio. There was no correlation
between the urinary cortisol/cortisone ratio and CRP
(r = 0.11, NS). There was no correlation between total urinary
corticosteroid metabolites and ESR or CRP (r = 0.29 and 0.08,
both NS).
Figure 5 Systemic measures of local glucocorticoid metabolism in patients with rheumatoid arthritis (RA) and non-inflammatory joint disease. (A, B)
Measurement of the balance of glucocorticoid activation/inactivation in non-inflammatory controls and patients with untreated RA. There was a
significant increase in the tetrahydrocortisol + allo-tetrahydrocortisol/tetrahydrocortisone (THF+alloTHF)/THE ratio in patients with inflammatory
arthritis, whereas the urinary free cortisol/cortisone ratio was unchanged. This indicated that 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1)-
mediated glucocorticoid activation was enhanced in patients with RA. (C, D) In patients with RA the relationship between the (THF+alloTHF)/THE ratio,
a systemic measure of 11b-HSD1 activity, and inflammatory markers was examined. The erythrocyte sedimentation rate (ESR), but not C-reactive
protein (CRP), demonstrated a significant correlation with this measure, suggesting increasing 11b-HSD1-mediated glucocorticoid activation with
increasing degrees of inflammation.
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DISCUSSION
By a variety of measures, substantial glucocorticoid metabolism
was identified in the joint. The net consequence was local
glucocorticoid excess. In patients with RA, glucocorticoid
generation within synovium, and systemic levels of active
steroid, correlated with disease activity and had functional
effects on the inflammatory response. Although this may form
part of an endogenous mechanism for immunoregulation, a
subset of synovial cells were able to inactivate glucocorticoids
through expression of 11b-HSD2 and thus may be glucocorti-
coid resistant.
Soon after the initial use of cortisone and hydrocortisone for
RA it was realised that these steroids were interconverted in
vivo and that 11b-HSD activity was essential for conversion of
cortisone to cortisol.25 This suggested that synovial tissue itself
might metabolise corticosteroids. Initially, it was thought that
patients with RA would have increased ability to inactivate
hydrocortisone.26 Although the understanding of tissue steroid
metabolism was rudimentary, bidirectional 11b-HSD activity
was noted in rheumatoid synovial tissue27 and significant
amounts of cortisol were generated from cortisone injected
into inflamed joints.28 Recently, interest has been renewed, with
reports implicating 11b-HSD2 expression in RA. 11b-HSD2 was
the most upregulated of .4300 genes in a study examining
PBMCs from patients with recent onset RA compared with
longstanding RA.18 11b-HSD2 was one of three (out of 20 000)
significantly upregulated genes in PBMCs from identical twins
discordant for RA.17 Analysis of rheumatoid synovium indicated
that 11b-HSD2 was expressed predominantly in synovial
macrophages. A separate study examined the capacity of
synovial explants to inactivate steroids and described how this
activity was higher in patients with RA.16 That study did not
involve direct measurement of glucocorticoid activation and
relied on 11b-HSD inhibitors with limited specificity.
Furthermore, the association between local and systemic
glucocorticoid metabolism was not assessed. To address this,
we used specific enzyme assays and selective inhibitors to define
the nature of glucocorticoid metabolising activity. We addition-
ally examined possible consequences of corticosteroid metabo-
lism on local and systemic levels of glucocorticoids.
The generation of substantial amounts of active glucocorti-
coids within the joint could account for the reason why
therapeutic glucocorticoids are so effective at dampening flares
of synovial inflammation. In the inflamed joint, cells will be
exposed to both circulating glucocorticoid and glucocorticoids
generated from circulating inactive precursors by cells expres-
sing 11b-HSD1. Locally produced glucocorticoids will be free to
diffuse into surrounding tissues. This could affect the integrity
of adjacent connective tissue. The periarticular osteoporosis
seen in RA is of multifactorial origin but high local glucocorti-
coid levels would suppress bone-forming ability and thus
contribute to uncoupling of bone resorption from formation.29
High glucocorticoid levels would also be expected to have an
immunosuppressive effect. This could contribute to the
increased risk of septic arthritis in RA.30
The finding of 11b-HSD2 expression in synovium raises the
possibility that some cells within synovium are resistant to
steroids through expression of this enzyme. Further assessment of
the functional implications of 11b-HSD2 expression is beyond the
scope of this study but there is a need to define further the
phenotype of 11b-HSD2-expressing synovial cells and to clarify
the relationship these cells have with 11b-HSD2-positive PBMCs.
An important and unexpected finding in this study is the presence
of considerable glucocorticoid metabolising capacity in synovium
from patients with OA. This tissue was initially used as a control
for patients with RA with the expectation that glucocorticoid
metabolism would be less prominent. However, net activity
appeared similar to that of RA. Additionally, the relative decrease
in IL6 production in response to cortisone treatment was similar.
The inability of the inhibitor to block the capacity of OA
synovium to convert cortisol to cortisone also suggests that 11b-
HSD2 is expressed. 11b-HSD2 expression in OA has been
identified in a previous study,16 which suggested that its
expression is lower in OA than RA. The roles of 11b-HSD1/2 in
OA remain to be defined.
Glucocorticoid activation was associated with ESR but not
CRP measurements. A potential explanation for this is the
confounding effect glucocorticoid activation had on synovial IL6
production. CRP synthesis is primarily an IL6-driven process
and thus the relationship between joint inflammation and CRP
will be complicated by the inhibitory effect of glucocorticoids
on IL6. The ESR is less dependent on IL6 and so less likely to be
directly influenced by local glucocorticoid metabolism.
The data presented here have several limitations. First,
synovial tissue was obtained from patients with RA treated
with various disease-modifying drugs. The small number of
patients studied makes it difficult to comment about potential
effects of antirheumatic treatment on steroid metabolising
enzyme activity. Second, synovial tissue was examined in
patients who had established RA. It will be of interest to study
temporal changes in glucocorticoid metabolism in patients with
RA at different disease stages and to assess whether findings are
specific to RA or a general feature of persistent synovial
inflammation. Although urinary measures of systemic steroid
metabolism correlated well with measures in synovial tissue and
fluid, an intrinsic limitation is that these might reflect altered
steroid metabolism in tissues other than synovium. We have
previously reported that inflammatory cytokines increase 11b-
HSD1 expression in fibroblasts from several tissues12 and 11b-
HSD1 expression has been reported in subpopulations of
peritoneal macrophages31 and T cells.32 Regardless of the extent
of altered glucocorticoid metabolism in RA, the functional
consequences of this deserve further study.
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